

# Assessing the Burden and Potential Strategies to Address Antimicrobial Resistance: A Workshop

March 4-5, 2024  
12:00 PM – 4:15 PM ET  
Virtual webcast

<b>Day 1: Assessing the Burden of AMR</b>	
<p><b>12:00 – 12:15 PM</b></p> <p>All times in U.S. Eastern (UTC-5)</p>	<p><b>Welcome Remarks, Workshop Overview, and Goals</b></p> <p><b>Introduction and Workshop Overview</b> Jomana Musmar, U.S. Department of Health and Human Services <i>Workshop chair</i></p>
<p><b>12:15 – 12:30 PM</b></p>	<p><b>Impact Story</b> Ken Opengart, Tyson Foods</p>
<p><b>12:30 – 1:30 PM</b></p> <p>12:30 – 12:45</p> <p>12:45 – 1:00</p> <p>1:00 – 1:15</p> <p>1:15 – 1:30</p>	<p><b>Session 1: Impact of AMR Across Medical Practice</b></p> <p><b>Moderator:</b> Helen Boucher, Tufts University</p> <p><b>Decolonization to Address Antimicrobial Resistance in Skilled Nursing Facilities</b> Susan Huang, University of California, Irvine</p> <p><b>Addressing Surgical Antimicrobial Overuse through Hospital-Level Benchmarking, Accountability, and Prioritization of Stewardship Efforts</b> Shawn Rangel, Boston Children's Hospital</p> <p><b>The Impact of Antimicrobial Resistance on Oncology Practice</b> John Wingard, University of Florida</p> <p><b>Q&amp;A</b></p>
<p><b>1:30 – 1:45 PM</b></p>	<p><b>BREAK</b></p>
<p><b>1:45 – 2:45 PM</b></p>	<p><b>Session 2: Monitoring AMR in Plants, Animals, and the Environment</b> <i>Do we truly understand the interconnectedness of the One Health sectors to AMR and how do we optimally bridge knowledge-to-action with limited resources?</i></p>

<p>1:45 – 2:00</p> <p>2:00 – 2:15</p> <p>2:15 – 2:30</p> <p>2:30 – 2:45</p>	<p><b>Moderator:</b> Ramanan Laxminarayan, One Health Trust</p> <p><b>Environmental Dimensions and Wastewater Surveillance</b> Joakim Larsson, University of Gothenburg</p> <p><b>Complexity of Monitoring and Comparing Data across One Health</b> Paul Plummer, Iowa State University College of Veterinary Medicine</p> <p><b>Quadripartite Collaboration for Multi-Sectoral Action on AMR</b> Suzanne Young, World Health Organization</p> <p><b>Q&amp;A</b></p>
<p>2:45 – 3:00 PM</p>	<p><b>BREAK</b></p>
<p>3:00 – 4:00 PM</p> <p>3:00 – 3:15</p> <p>3:15 – 3:30</p> <p>3:30 – 3:45</p> <p>3:45 – 4:00</p>	<p><b>Session 3: Making Meaning from Metrics: What’s at Stake?</b> <i>Is the full scope of AMR being captured and quantified, and how?</i></p> <p><b>Moderator:</b> Chris Braden, U.S. Centers for Disease Control and Prevention</p> <p><b>Global Surveillance of AMR: Complementary Methods to Address Global Data Scarcity</b> Olga Tosas, World Health Organization</p> <p><b>Addressing Antimicrobial Resistance: Investing in Prevention and Measuring Success</b> Dawn Sievert, U.S. Centers for Disease Control and Prevention</p> <p><b>Burden of AMR-Associated Infections Preventable by Interventions</b> Joseph Lewnard, University of California, Berkeley</p> <p><b>Q&amp;A</b></p>
<p>4:00 – 4:15 PM</p>	<p><b>Synthesis and Adjourn</b> Matthew Zahn, Orange County Health Care Agency Jomana Musmar, U.S. Department of Health and Human Services <i>Workshop chair</i></p>
<p><b>END OF DAY 1</b></p>	

## Day 2: Improving Strategies to Address AMR

<b>12:00 – 12:15 PM ET</b>	<b>Welcome Remarks, Review of Day 1</b>  Jomana Musmar, U.S. Department of Health and Human Services <i>Workshop chair</i>
<b>12:15 – 12:30 PM</b>	<b>Impact Story</b> Anthony Darcovich, World Health Organization AMR Survivors Taskforce
<b>12:30 – 1:30 PM</b>	<b>Session 4: Stewardship</b> <i>Envision the future: 10 years from now, what will we have done that will have gotten us to the place we ideally need to be, what is intended outcome and measure, how do we reach it?</i>  <b>Moderator:</b> Julia Szymczak, University of Utah
12:30 – 12:45	<b>Outpatient Telehealth and Antimicrobial Stewardship</b> Kristin Ray, UPMC Children’s Hospital of Pittsburgh
12:45 – 1:00	<b>Diagnostics as a Resistance Combatting Strategy</b> Robin Patel, Mayo Clinic
1:00 – 1:15	<b>Challenges and Opportunities in Inpatient Antimicrobial Stewardship</b> Ritu Banerjee, Vanderbilt University Medical Center
1:15 – 1:30	<b>Q&amp;A</b>
<b>1:30 – 1:45 PM</b>	<b>BREAK</b>
<b>1:45 – 2:45 PM</b>	<b>Session 5: Access</b> <i>How do we make access work? Dissecting different degrees of access issues and draw compare/contrast (if appropriate) between global vs US settings.</i>  <b>Moderator:</b> Elizabeth Hermsen, Pfizer
1:45 – 2:00	<b>Protecting Pharmaceutical Supply Chains in LMICs</b> Anthony McDonnell, Center for Global Development
2:00 – 2:15	<b>Appropriate Access to Existing and Novel Antibiotics</b> Jennifer Cohn, Global Antibiotic Research & Development Partnership

<p>2:15 – 2:30</p> <p>2:30 – 2:45</p>	<p><b>Sustainable Use of Available Medicines</b> Esmita Charani, University of Cape Town</p> <p><b>Q&amp;A</b></p>
<p><b>2:45 – 3:00 PM</b></p>	<p><b>BREAK</b></p>
<p><b>3:00 – 4:00 PM</b></p> <p>3:00 – 3:15</p> <p>3:15 – 3:30</p> <p>3:30 – 3:45</p> <p>3:45 – 4:00</p>	<p><b>Session 6: Innovation</b> <i>How do we ensure truly new candidates are entering trials and getting into clinical use?</i></p> <p><b>Moderator:</b> Greg Frank, Merck &amp; Co.</p> <p><b>Artificial Intelligence for Antibiotic Discovery</b> James Collins, Massachusetts Institute of Technology</p> <p><b>The TB Drug Accelerator: A Public-Private Model for Antibiotic Development</b> Ken Duncan, Bill &amp; Melinda Gates Foundation</p> <p><b>Supporting New Antimicrobials in Clinical Use</b> Ramy Elshaboury, Massachusetts General Hospital</p> <p><b>Q&amp;A</b></p>
<p><b>4:00 – 4:15 PM</b></p>	<p><b>Synthesis and Close</b></p> <p>Jomana Musmar, U.S. Department of Health and Human Services <i>Workshop chair</i></p>
<p><b>END OF WORKSHOP</b></p>	